NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Candel Therapeutics, Inc. (CADL) Stock Analysis

Candel Therapeutics, Inc. (CADL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CADL

$12.78

−$0.19 (−1.46%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CADL with… →

CADL Key Statistics

As of Sep 4, 2026
Trading
Open
$12.91
Previous Close
$12.97
Day's Range
12.76–13.05
52-Week Range
4.35–14.00
Volume
535.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.47
Valuation
Market Cap
$977.91M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.45
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$38.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
76.52M
1-Year Return
+161.08%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.53M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CADL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+126.19%
2025−34.91%
2024+490.48%
2023−17.88%
2022−77.11%
2021 (partial year)+11.71%

As of September 4, 2026.

CADL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$38.18M—
2024$0.00−$55.18M—
2023$0.00−$37.94M—
2022$125.00K−$18.79M−15035.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$48.18M−$38.18M—
2024$0.00—−$33.37M−$55.18M—
2023$0.00—−$38.39M−$37.94M—
2022$125.00K—−$34.67M−$18.79M−15035.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CADL Valuation vs Biotechnology Median

Median of 656 stocks
MetricCADLBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Candel Therapeutics, Inc. (CADL) carries a market capitalisation of $977.91M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 55.

CADL last closed at $12.78 on September 4, 2026. That is −$0.19 (−1.46%) against the previous close. Over the past 52 weeks the price has ranged from $4.35 to $14.00. The latest close sits 193.79% above that 52-week low.

Financial Health

In fiscal 2025, Candel Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $38.18M. Profit margin runs at 0%. Trailing earnings per share are −1.45.

Across the 4 fiscal years on file, revenue moves from $125.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned +161.08%. Measured over 5 years, that is +9.41% a year compounded. The reported beta is −0.47. Annualized volatility over the trailing 5 years is 164.36%.

Growth & Income

No dividend is on file for CADL.

So far in 2026 the price is +126.19%. The strongest complete calendar year on file is 2024 at +490.48%; the weakest is 2022 at −77.11%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Candel Therapeutics, Inc. (CADL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Candel Therapeutics, Inc. CADL $977.91M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Candel Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Visit website →